Bros. Advisors Lp Baker Purchases 807,338 Shares of Immunocore Holdings plc (NASDAQ:IMCR) Stock

Immunocore Holdings plc (NASDAQ:IMCR) Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now owns 2,144,060 shares in the company, valued at $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Immunocore Price Performance

NASDAQ IMCR opened at $30.43 on Friday. Immunocore Holdings plc has a 12 month low of $27.19 and a 12 month high of $66.00. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The firm has a market capitalization of $1.52 billion, a PE ratio of -32.03 and a beta of 0.79. The company’s 50 day simple moving average is $30.00 and its 200 day simple moving average is $31.20.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IMCR. Jefferies Financial Group Inc. bought a new stake in Immunocore during the fourth quarter worth approximately $4,868,000. GF Fund Management CO. LTD. bought a new stake in Immunocore during the fourth quarter worth approximately $25,000. Woodline Partners LP boosted its holdings in Immunocore by 19.4% during the fourth quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock worth $9,678,000 after buying an additional 53,378 shares in the last quarter. Tang Capital Management LLC boosted its holdings in Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock worth $45,890,000 after buying an additional 450,000 shares in the last quarter. Finally, Tema Etfs LLC bought a new stake in Immunocore during the fourth quarter worth approximately $330,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on IMCR shares. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 target price on shares of Immunocore in a report on Friday, March 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $71.00 target price on shares of Immunocore in a report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $65.64.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.